Overview
Eisai is a Japanese research-based pharmaceutical company that discovers, develops, and markets prescription medicines under its "human health care (hhc)" concept. Its portfolio concentrates on neurology and oncology, including LEQEMBI (lecanemab), an anti-amyloid treatment for Alzheimer's disease now offered in intravenous and subcutaneous forms; lemborexant for insomnia; and the anticancer agent Halaven, developed through worldwide R&D and open-innovation partnerships. The company also runs a global health program that supplies medicines to more than 30 countries, having distributed billions of tablets to help eliminate neglected tropical diseases such as lymphatic filariasis. What sets Eisai apart is this hhc concept, which frames access and affordability—not only innovation—as central to its mission. The goal is to empower people to realize their fullest life by advancing treatments for conditions such as dementia and cancer.
Work here?Claim your company
Simplify's take
What believers are saying
- Eisai reported Q2 fiscal 2026 revenue of ¥470 billion on November 11, 2026.
- Leqembi generated ¥61.5 billion in first-half fiscal 2026 revenue, with U.S., Japan, China growth.
- Five-year Clarity AD data at CTAD 2026 should strengthen payer and physician confidence.
What critics are saying
- Eli Lilly’s Kisunla competes directly with fixed-duration dosing and simpler patient messaging.
- European regulators already flagged Leqembi safety; another rejection would slow ex-U.S. expansion.
- Leqembi litigation over ARIA disclosure and informed consent can escalate into expensive reputational damage.
What makes Eisai unique
- LEQEMBI Pen launched in Japan on November 13, 2026, enabling at-home anti-amyloid dosing.
- Eisai leads global lecanemab development, regulatory filings, and commercialization with Biogen since 2014.
- Lecanemab is approved in 53 countries and regions, giving Eisai unmatched Alzheimer’s breadth.
Help us improve and share your feedback! Did you find this helpful?